Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Methylnaltrexone for opioid-induced constipation in advanced illness
NCT00401362Phase 3Completed
- Sponsor
- Valeant Pharmaceuticals
- Start
- Feb 2003
- Primary completion
- Feb 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of methylnaltrexone in opioid-induced constipation (OIC) (3 arms), sponsored by Valeant Pharmaceuticals. Primary endpoint: Efficacy of SC MNTX compared with placebo in inducing laxation at 29 days. Started Feb 2003; status: completed.
02
Drugs
methylnaltrexone
03
Conditions
opioid-induced constipation (OIC)
Beyond the preview
Go deeper on NCT00401362.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00401362.